Screening and Model Systems for Therapies of Alzheimer Disease (AD)
A new strategy for the therapy of AD describes that moderate enhancement of the α-secretase ADAM10 completely inhibits amyloid plaque deposition and enhances the production of the N-terminal domain of the amyloid precursor protein (APP), that acts as neuropotective component. As a consequence, these effects improve synaptic plasticity and reduces cognitive defects shown in a transgenic mouse model for AD.
Further Information: PDF
IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-0
Contact
Dr. Klaus Kobek
